Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development
and sale of broadly enabling, pressure-based technology and products to the
worldwide life sciences and other industries, today announced its receipt of
two additional purchase orders for its revolutionary BaroShear(TM) K45
processing system. According to the update, the BaroShear K45, based on the
company’s proprietary Ultra Shear Technology(TM) (“UST”) platform, is a unique
and powerful nanoemulsification system designed to resolve one of the CBD
industry’s most critical problems: the extremely poor solubility of CBD Oil in
water. “We fully appreciate both the challenges and the significant emerging
market opportunity of having the ability to deliver CBD in a form that allows
for greater absorption and enhanced bioavailability,” NanoPeak Solutions, Inc.
President Bruce Leitch said in the news release. “Multiple scientific studies
have indicated that CBD should be processed via nanoemulsion technology in
order to be truly water soluble and resulting in consumer products possessing
both shelf stability and consistent dosages. NanoPeak has spent significant
time reviewing and assessing various nanoemulsification platforms and the
Company has great confidence that PBI’s BaroShear K45 System will be
instrumental in NanoPeak having the ability to offer the highest quality
ingredients to be utilized in CBD products of all types.”
To view the full press release, visit http://ibn.fm/vCcwx
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
